Laura Q.M. Chow, M.D., FRCPC
Associate Director of Clinical Research, Livestrong Cancer Institutes
Director of Lung, Head, Neck & Clinical Immunotherapy Programs, Livestrong Cancer Institutes
Professor, Department of Oncology
Associate Chair of Education, Department of Oncology
University of British Columbia; Vancouver, British Columbia
Residency, Internal Medicine
University of Alberta; Edmonton, Alberta
Fellowship, Medical Oncology
University of Calgary, Tom Baker Cancer Center; Calgary, Alberta
Laura Chow is a professor of oncology with tenure and the associate chair of education in the Department of Oncology at Dell Medical School. She is also director of thoracic, head and neck malignancies and clinical immunotherapy programs and the associate director of clinical research at Livestrong Cancer Institutes.
Previously, Chow spent more than nine years as the associate director of the phase I developmental therapeutics program and attending medical oncologist in lung, head and neck malignancies at Seattle Cancer Care Alliance; associate member of clinical research at the Fred Hutchinson Cancer Research Center; and a professor in the Department of Medicine, Division of Oncology at the University of Washington.
Chow came to medicine with a background in pharmacology and therapeutics and was inspired to pursue a career in oncology because of her personal experiences with cancer in her family as well as her interest in clinical research.
Chow has extensive clinical trials experience; a strong background in clinical pharmacology, therapeutics and developmental therapeutics; and excellent Canadian and USA internal medicine and clinical medical oncology skills and training. Her clinical expertise is in head and neck cancers, thyroid cancer and lung cancers with a national and international reputation as a researcher focused on novel therapeutics and early phase clinical trials, immunotherapy and head and neck cancers, thyroid cancers and lung cancers. She has helped develop and bring forth many novel drugs, including the PD-1 immune-checkpoint inhibitors, into regulatory approval as standard-of-care treatments for head and neck cancers and lung cancer. She has been the lead principal investigator of over 40 early phase thoracic and head and neck cancer trials with over 65 publications in high-impact journals, with a clinical research interest focused on developing novel lung and head and neck cancer immune-checkpoint therapies and new combination immunotherapeutics.
Chow enjoys teaching and believes strongly in patient-centered clinical care. In addition to English, she is fluent in Cantonese and conversational French. In her spare time, she runs, cycles, pursues fitness classes, cooks, bakes and loves spending time with her husband and 5-year-old son.
American Society of Clinical Oncology
American Association of Clinical Research
National Cancer Institute
NCI Cancer Immunotherapy Trials Network
NCI Investigational New Drug Task Force/Working Group
Development Therapeutics/Research & Development Award
Canadian Association of Medical Oncologists, 2004-2006